Navigation Links
Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Date:1/9/2008

and Director, Clinical Investigation and Translational Research in the Department of Lymphoma/Myeloma, M.D. Anderson Cancer Center and a principal investigator for this trial. "There have been no new approved therapies in relapsed/refractory Hodgkin lymphoma for decades. As epigenetics is thought to play a role in lymphoma, this clinical study will help build an understanding of the role of HDAC inhibitors and demethylating agents in the treatment of non-Hodgkin and Hodgkin lymphoma."

Encouraging anti-tumor activity has been demonstrated in a Phase 2 clinical study of MGCD0103 as a single agent in the relapsed or refractory Hodgkin lymphoma patient population. Data from the ongoing study, presented at the American Society of Hematology (ASH) annual meeting last month, reported an objective complete and partial response (CR and PR) rate of 38 percent and a disease control rate of 43 percent in 21 evaluable patients in the 110mg cohort. Eighty-six percent of patients who had CT scans experienced a reduction in tumor size, with 57 percent experiencing a tumor reduction of greater than 30 percent. The two CR patients have a preliminary progression-free survival (PFS) of 14 and nine months at the time of analysis, and the range of PFS from the responder group is 56 to greater than 396 days. Adverse events associated with MGCD0103 administration of grade 3 or higher included pneumonia (15 percent), thrombocytopenia (12 percent) and fatigue (nine percent). Dose modification was effective in many of these patients.

About MGCD0103

MGCD0103 is an orally-administered, isotype-selective HDAC inhibitor. The compound is currently in one Phase 1 combination clinical trial with Taxotere(R) for solid tumors, two Phase 1/2 combination trials with Vidaza(R) for hematological malignancies and with Gemzar(R) for pancreatic cancer; and five Phase 2 clinical trials in hematological malignancies.

MGCD0103 has received orphan drug designation from the U.S. Food a
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
3. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
4. Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
5. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
6. GlaxoSmithKline and Theravance Announce Start of Large Phase 2B ICS and LABA Studies for Asthma in the Horizon Program
7. Elekta Announces Clinical Start-Up of New Leksell Gamma Knife(R) Perfexion(TM) at UPMC
8. InterMune Announces Start of Phase 1b Trial of ITMN-191
9. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
10. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
11. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Valeant Pharmaceuticals International, Inc. (NYSE: ... company,s Bridgewater, New Jersey location ... Drug Administration (FDA) relating to an inspection in June ... Aesthetic injectable, which was divested to Galderma S.A. in ... Valeant,s contract manufacturers (rather than Valeant,s own internal manufacturing) ...
(Date:9/30/2014)... 30, 2014  Based on its recent analysis ... Sullivan recognizes Ventana Medical Systems, Inc. (Ventana), a ... North American Frost & Sullivan Award for Technology ... with a focus on innovation and improving patient ... tissue-based cancer diagnostic solutions for patients worldwide. ...
(Date:9/30/2014)... The report based on "Nutraceutical ... Growth and Forecast, 2007 - 2017," elaborated by Transparency ... billion in 2012 and is further expected to reach ... of 7.3% from 2012 to 2017. Nutraceutical ... especially to prevent chronic diseases that may occur to ...
Breaking Medicine Technology:Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 2Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 3Nutraceutical Ingredient Market Will Reach USD 33.6 Billion Globally in 2018: Transparency Market Research 4
... , REDWOOD CITY, Calif., Dec. 15 ... results from five new studies on its Onco type ... currently use to predict the likelihood of chemotherapy benefit and ... were presented at the 32nd Annual CTRC-AACR San Antonio Breast ...
... , , , WALTHAM, Mass., Dec. 15 Decision Resources, ... pharmaceutical and healthcare issues, finds that an overall survival benefit ... European oncologists in their decision to prescribe a novel agent ... The new Special European Physician & Payer Forum report entitled ...
Cached Medicine Technology:Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 2Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 3Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 4Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 5Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 6Genomic Health Announces New Data Reinforcing Clinical Utility of Oncotype DX(R) in Multiple Breast Cancer Populations 7For Breast Cancer Treatment, an Agent That Can Achieve an Overall Survival Benefit Would Pose the Greatest Challenge to Avastin's Dominance in Europe 2For Breast Cancer Treatment, an Agent That Can Achieve an Overall Survival Benefit Would Pose the Greatest Challenge to Avastin's Dominance in Europe 3
(Date:9/30/2014)... 30, 2014Levothyroxine (L-T4), long the standard of care ... but some individuals do not regain optimal health ... may help to explain these differences. An expert ... thyroid hormone replacement reviewed the latest studies on ... whether a change to the current standard of ...
(Date:9/30/2014)... at the University of Pittsburgh School of Dental Medicine ... the National Institute of Dental and Craniofacial Research, part ... exploration of the genetic roots of cleft lip and ... populations in Colombia, Nigeria, the Philippines and Pennsylvania. ... the lip or palate that can form when a ...
(Date:9/30/2014)... muscles contain few stem cells, heart tissue is ... Now Tel Aviv University researchers are literally setting ... , Dr. Tal Dvir and his graduate student ... of Materials Science and Engineering, and Center for ... and nanotechnological tools ranging in size from ...
(Date:9/30/2014)... a very valuable procedure by which to screen ... seems that healthy Americans who do undergo this ... before they actually should. Gina Kruse of ... advise that endoscopists stick to the national guidelines ... Journal of General Internal Medicine , published by ...
(Date:9/30/2014)... SIMpalm, the top iPhone app development ... great social networking music sharing experience. Lyricz LLC officially ... and iPod touch®. The App allows users to take ... pre-populated ITunes account. This app also gives users the ... photo of their choice to the snippet of selected ...
Breaking Medicine News(10 mins):Health News:New hypothyroidism treatment guidelines from American Thyroid Association 2Health News:Pitt team searches for genetic roots of cleft lip, palate 2Health News:A heartbeat away? Hybrid 'patch' could replace transplants 2Health News:Americans undergo colonoscopies too often, study finds 2Health News:LYRICZ App for iPhone®, Helps You Share Images with Music to Inspire and Influence 2
... need in ... exploding HSA market, ... an online education, enrollment, and incentive support platform for,Group Health ... Health platform (http://www.fontishealth.com ) simplifies the,administration and use of ...
... The following is a,statement regarding Microsoft,s announcement of ... It is encouraging that companies like Microsoft, Google ... (PHR) products and systems,that people can use to manage ... follow suit. Having ready access to your own,health information ...
... tick-borne illness has nearly tripled, research shows , THURSDAY, Oct. ... fever in the United States almost tripled from 695 in ... fatal disease is caused by Rickettsia rickettsii bacteria, ... dog tick or Rocky Mountain wood tick. Within 14 days ...
... 4, 2007 MedImmune, Inc. today announced results from ... Society of America (IDSA) 45th Annual Meeting adding to ... RSV is a viral pathogen that produces annual ... manifests cold-like symptoms in healthy children, it can prove ...
... General,Dentistry (AGD) was extremely disappointed by President Bush,s ... Program (SCHIP),reauthorization bill. The SCHIP bill agreed upon ... important and beneficial dental,provisions intended to provide for ... Bush, who had threatened to veto this bill,followed ...
... Health Coaching Service,with HealthVault,s Best-Of-Breed Health ... and Compatibility with Other Related Devices,and ... LiveHealthier,announced today the compatibility of its ... HealthVault, the newly launched consumer health,platform. ...
Cached Medicine News:Health News:Fontis Health Launches Online HSA Support System 2Health News:Statement Regarding Microsoft's Announcement of New Services to Help People Store Their Health Information Online 2Health News:Surge in U.S. Cases of Rocky Mountain Spotted Fever 2Health News:Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results 2Health News:AGD Concerned With Presidential Veto of SCHIP Reauthorization Bill 2Health News:AGD Concerned With Presidential Veto of SCHIP Reauthorization Bill 3Health News:LiveHealthier Announces Its Health and Wellness Coaching Solution for Employer Groups is Now Compatible With Microsoft HealthVault 2
Used for the retrieval of stones, stents, or other objects in the urinary tract under direct vision. Retrieval Forceps are designed for use through rigid or flexible endoscopes. Supplied sterile in p...
... technology allows the grasper ... a shorter length and ... the stone. The Unidex ... one-handed operation. Supplied sterile ...
Bugbee Fulgurating...
Fulgurating Electrode, 2 F...
Medicine Products: